Last reviewed · How we verify
Perdipine injection
At a glance
| Generic name | Perdipine injection |
|---|---|
| Also known as | nicardipine |
| Sponsor | Astellas Pharma China, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
- Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage (PHASE4)
- Hypotensive Anesthesia for Orthognathic Surgery (PHASE4)
- Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial (NA)
- The Intra-arterial Vasospasm Trial (PHASE4)
- Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine (EARLY_PHASE1)
- Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment (NA)
- Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perdipine injection CI brief — competitive landscape report
- Perdipine injection updates RSS · CI watch RSS
- Astellas Pharma China, Inc. portfolio CI